Confidential S-1 Filing: 2026 Practitioner Walkthrough

A confidential S-1 filing lets a company run the full SEC review process privately before committing to a public IPO. The draft never appears on EDGAR until the company chooses to proceed, which means you can receive comments, revise the document, and even walk away entirely without a single public disclosure.

What most existing guides miss is how dramatically the rules changed on March 3, 2025. The SEC's Division of Corporation Finance expanded confidential submission eligibility to cover virtually every Securities Act offering and Exchange Act registration, not just first-time IPOs. OpenAI's June 8, 2026 confidential S-1 announcement brought the process back into mainstream conversation, but the mechanics that matter to your finance and legal team are more nuanced than the headlines suggest.

This walkthrough covers who is eligible in 2026, the exact timing rules for each transaction type, the critical asymmetry for follow-on offerings, and the strategic calculus your CFO needs before choosing the confidential route.

Key takeaway: Since March 2025, any company, at any stage of its public life, can submit a draft registration statement confidentially for any Securities Act offering or Exchange Act registration. The 12-month post-IPO window that previously limited follow-on offerings no longer applies.

What Is a Confidential S-1 Filing?

A confidential S-1 filing is a draft registration statement (submitted on Form DRS via EDGAR) that the SEC's Division of Corporation Finance reviews privately, without the document becoming publicly visible. The company engages in a full comment-and-response cycle with SEC staff before deciding whether to proceed with a public offering.

The process originated with the JOBS Act of 2012, which allowed emerging growth companies (EGCs) to submit draft IPO registration statements confidentially. In 2017, the SEC staff extended the accommodation to all companies for IPOs and follow-on offerings within 12 months of their IPO. The March 2025 expansion removed nearly all remaining restrictions.

One important caveat: this is SEC staff policy, not a formal rule adopted through notice-and-comment rulemaking. The staff can modify or withdraw the accommodation without going through the formal rulemaking process, per Willkie Farr's analysis of the March 2025 announcement. That distinction matters if your transaction timeline is long and you need certainty about the process being available.

For a full explanation of what the S-1 itself contains and how the SEC review process works, see Finrep's S-1 disclosure requirements guide and the practitioner's S-1 walkthrough.

Who Is Eligible to File a Confidential S-1 in 2026?

As of March 2025, eligibility is broad: any company can submit a draft registration statement confidentially for any Securities Act offering or Exchange Act registration, regardless of how long it has been public.

The eligibility matrix post-2025 looks like this:

EGC status still matters beyond confidential filing. EGCs, defined as companies with less than $1.07 billion in annual revenue in their most recently completed fiscal year, retain additional benefits: two years of audited financial statements instead of three, and the ability to test the waters with qualified institutional buyers and institutional accredited investors before filing. If your company is on the EGC boundary, that threshold is worth tracking separately. See Finrep's emerging growth company status guide for the full picture.

How the Confidential S-1 Process Works: Step by Step

Step 1: Submit Form DRS on EDGAR

The company submits its draft registration statement using Form DRS on EDGAR. The submission is not publicly visible during the confidential review period. It only appears on EDGAR when the company publicly files its registration statement and simultaneously files all previously non-public drafts.

The draft should be substantially complete. The SEC expects a document close to final form, though it recognizes that some financial information, such as a fiscal period that has not yet closed, may not be ready at the time of initial submission.

New in March 2025: Companies may omit underwriter names from the initial draft submission, even where Items 501 and 508 of Regulation S-K would otherwise require them. Underwriter names must appear in subsequent confidential submissions and in the publicly filed registration statement. This is practically useful because syndicate selection is often not finalized when the initial draft goes in.

Step 2: SEC Staff Review and Comment Letters

After submission, the Division of Corporation Finance assigns the filing to the relevant industry group and begins its review. Staff then issue written comments, asking for specific changes, additional disclosures, or supplemental information.

The company responds, and this back-and-forth may run through several rounds. All of it happens privately under the confidential process. With a public filing, each amendment is visible on EDGAR and can generate media speculation about problems with the company or its financials. The confidential process eliminates that pressure.

Note: after the offering becomes effective, the SEC publicly releases staff comment letters and the company's responses on EDGAR, no earlier than 20 business days after effectiveness. The comments eventually become public, just not during the sensitive pre-IPO period.

Step 3: Decide Whether to Proceed

After receiving SEC feedback, the company makes a go/no-go decision. This is the most underappreciated feature of the confidential process.

If the company decides not to proceed, it can withdraw the draft without any public disclosure. The filing never appears on EDGAR. Compare that to a public S-1 withdrawal, which is visible to the market and can signal distress or failed investor interest.

OpenAI's June 2026 announcement illustrates the optionality the process creates. The company stated: "We have not decided on timing yet; it may be a while because there are things we want to do that are likely easier as a private company. But it's a complicated set of tradeoffs and this gives us the option to go public sooner if that ends up being best." That is exactly what the confidential process is designed for: preserving flexibility without forcing a public commitment.

Step 4: Public Filing and the Timing Rules

This is where practitioners make the most mistakes. The timing rules differ by transaction type, and the differences are material.

All previously non-public draft submissions must be filed publicly at the same time as the registration statement. Investors and the market get to see the full revision history, not just the final version.

For IPOs, the 15-day window before the roadshow is tight. Most companies commence their roadshow the day after the mandatory waiting period expires, which means the public filing date effectively sets the roadshow start date. Build that into your close calendar.

For follow-on offerings, the 2-business-day window is short enough that SEC staff comments on the publicly filed version can disrupt pricing timing. The SEC's own guidance explicitly notes that staff may comment on such public filings, which could impact a company's desired effectiveness timing. That is not a theoretical risk.

The Critical Asymmetry for Follow-On Offerings

Warning: For follow-on Securities Act offerings and Exchange Act registrations, only the initial registration statement may be submitted confidentially. All amendments, including amendments responding to SEC staff comments, must be filed publicly.

This is the most important limitation the March 2025 expansion did not change, and it is the one most practitioners overlook.

For an IPO, the entire comment-and-response cycle happens privately. For a follow-on offering, the initial draft gets confidential review, but the moment you file publicly to start the 2-business-day clock, any subsequent amendment is on EDGAR for the world to see. If SEC staff then comment on the public filing, your response amendment is also public. That can expose your pricing timeline and invite competitive scrutiny at exactly the wrong moment.

The practical implication: for follow-on offerings, the confidential process buys you time to get the document substantially clean before going public, but it does not insulate you from public scrutiny during the amendment phase the way an IPO confidential process does. Factor that into your decision.

When to Use the Confidential Process, and When Not To

The confidential route is not always the right choice. Here is the strategic calculus:

Use confidential filing when:

• You want maximum flexibility to adjust timing based on market conditions or SEC feedback
• The company has sensitive competitive information that would be damaging if disclosed prematurely
• You want the option to withdraw without public disclosure if the process reveals problems
• You have not finalized your underwriting syndicate and want to omit underwriter names from the initial draft
• You are a de-SPAC target that qualifies for confidential submission and want to avoid premature market signaling

Consider public filing when:

• You want to signal commitment to the market and accelerate investor education before the roadshow
• Your business is well-known and the filing itself is a marketing event (some high-profile companies deliberately file publicly to generate buzz)
• Speed to market is the overriding priority and you are confident the document is clean enough to avoid multiple comment rounds
• You are a well-seasoned issuer with a shelf registration already effective and the follow-on is straightforward

The confidential process is not free. It adds time to the overall IPO timeline because the SEC review happens before the public filing clock starts. For companies in a hot market window, that delay can be costly. Weigh the optionality against the time cost.

What "Confidential" Actually Means in Practice

Three common misconceptions:

1. The SEC does see it. The Division of Corporation Finance reviews the draft fully, issues comments, and expects substantive responses. "Confidential" means not publicly visible, not that the SEC is not scrutinizing it.

2. It will eventually become public. If you proceed with the offering, the draft and all amendments are filed publicly at least 15 days before the roadshow (for IPOs). The comment letters and responses follow after effectiveness. Plan your disclosure strategy accordingly.

3. Rule 135 governs what you can say publicly during the confidential period. Rule 135 under the Securities Act of 1933 (17 CFR 230.135) provides a safe harbor allowing a company to announce a planned registered offering without that announcement constituting an "offer" under the Securities Act, provided the notice contains only limited information: the issuer's name, the title and amount of securities, and the anticipated timing. OpenAI's June 2026 announcement was made explicitly pursuant to Rule 135. That is the standard mechanism for communicating about a planned IPO while the draft is confidential.

Gun-jumping, the prohibition on conditioning the market for an offering before the registration statement is effective, applies during the confidential period. Any communication beyond what Rule 135 permits, or beyond the testing-the-waters accommodation available to EGCs, risks a gun-jumping violation that could delay or derail the offering. Coordinate with securities counsel before any public statement about the planned offering.

De-SPAC Transactions and the 2025 Expansion

The March 2025 guidance addressed a gap that had created uncertainty in the SPAC market. Under SPAC rules that became effective in July 2024, target companies in de-SPAC transactions must be co-registrants in certain structures where the SPAC survives the business combination.

The SEC has now clarified that these registration statements are eligible for confidential submission where the SPAC is the surviving entity (the SPAC-on-top structure), as long as the target company would itself qualify for confidential submission under existing policies. If the target is a private company that would qualify as an EGC or that would otherwise be eligible, the de-SPAC registration statement can go through the confidential review process.

This is a meaningful development for SPAC sponsors and their counsel. For the broader SPAC vs. IPO strategic question, see Finrep's SPAC vs. IPO decision framework.

FAQ

Can a foreign private issuer use the confidential S-1 process? Yes. Foreign private issuers file on Form F-1 for IPOs and Form 20-F for Exchange Act registration. Both are eligible for confidential submission. The March 2025 expansion explicitly includes Forms 20-F and 40-F (used by Canadian companies under the Multijurisdictional Disclosure System). FPIs that qualify as EGCs can also use the EGC-specific confidential submission procedures.

What happens if we decide not to proceed after filing confidentially? The draft never becomes public. You can withdraw without any public disclosure. This is a significant advantage over a public filing, where withdrawal is visible on EDGAR and can signal distress or failed investor interest.

Can we omit our underwriters from the initial draft submission? Yes, as of March 2025. Underwriter names may be omitted from the initial draft where otherwise required by Items 501 and 508 of Regulation S-K, provided they are included in subsequent submissions and in the public filing.

Does the confidential process apply to Exchange Act registrations, not just IPOs? Yes. Since March 2025, Forms 10, 20-F, and 40-F filed to register a class of securities under Exchange Act Section 12(b) or 12(g) are eligible. The timing rules differ: 30 days before effectiveness for Section 12(b), and 60 days for Section 12(g).

Is the confidential submission process a formal SEC rule? No. It is SEC staff policy, not a rule adopted through notice-and-comment rulemaking. The staff can modify or withdraw the accommodation without formal rulemaking. Practitioners who need certainty about the process being available for a long-dated transaction should note this distinction.

How does the confidential process interact with Regulation FD? Regulation FD generally prohibits selective disclosure of material nonpublic information to certain market participants. During the confidential period, the draft registration statement itself is nonpublic. Communications about the planned offering should be limited to what Rule 135 permits (or the testing-the-waters accommodation for EGCs) to avoid both gun-jumping and Regulation FD issues. Coordinate with securities counsel on any investor outreach during the confidential period.

For the full IPO preparation checklist, including governance, financial statement requirements, and the roadshow process, see Finrep's IPO due diligence checklist and IPO roadshow process walkthrough.